Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae

This publication has 58 references indexed in Scilit:

• A New Imperative for Global Pneumonia Control: A Commentary
  The Pediatric Infectious Disease Journal, 2007
• Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine Coverage
  JAMA, 2007
• Relative Roles of Genetic Background and Variation in PspA in the Ability of Antibodies to PspA To Protect against Capsular Type 3 and 4 Strains of Streptococcus pneumoniae
  Infection and Immunity, 2003
• Age-dependent preference in human antibody responses toStreptococcus pneumoniaepolypeptide antigens
  Clinical and Experimental Immunology, 2002
• Pneumococcal Surface Protein A of InvasiveStreptococcus pneumoniaeIsolates from Colombian Children
  Emerging Infectious Diseases, 2001
• Pneumococcal Surface Protein A of InvasiveStreptococcus pneumoniaeIsolates from Colombian Children
  Emerging Infectious Diseases, 2001
• Complement
  New England Journal of Medicine, 2001
• Truncated Streptococcus pneumoniae PspA Molecules Elicit Cross-Protective Immunity against Pneumococcal Challenge in Mice
  The Journal of Infectious Diseases, 1996
• Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).
  The Journal of Experimental Medicine, 1987
• Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.
  The Journal of Experimental Medicine, 1984